Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Факторы риска формирования и прогрессирования фиброза печени при неалкогольной жировой болезни печени: обзор литературы и собственные данные
Факторы риска формирования и прогрессирования фиброза печени при неалкогольной жировой болезни печени: обзор литературы и собственные данные
Кролевец Т.С., Ливзан М.А. Факторы риска формирования и прогрессирования фиброза печени при неалкогольной жировой болезни печени: обзор литературы и собственные данные. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019; 3: 21–26. DOI: 10.26442/26583739.2019.3.190486
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Целью данной публикации стала актуализация информации о неалкогольной жировой болезни печени. Подробно рассмотрены возможные клинические и лабораторные факторы прогрессирования фиброза печени при неалкогольной жировой болезни печени. Представлены собственные результаты открытого исследования «случай–контроль» с включением 149 пациентов с неалкогольной жировой болезнью печени. Выявлено, что наиболее информативными маркерами формирования и прогрессирования фиброза печени являются абдоминальный тип ожирения (увеличение объема талии) в сравнении с общей оценкой избыточной массы тела или ожирения по индексу массы тела, а также лептинорезистентность в сравнении с инсулинорезистентностью. Представлена математическая модель, разработанная на основе комплексного количественного анализа клинических, инструментальных и лабораторных показателей, которая позволяет прогнозировать формирование и прогрессирование фиброза печени у лиц с неалкогольной жировой болезнью печени.
Ключевые слова: неалкогольная жировая болезнь печени, фиброз, прогрессирование, прогноз, факторы.
Key words: non-alcoholic fatty liver disease, fibrosis, progression, prognosis, factors.
Ключевые слова: неалкогольная жировая болезнь печени, фиброз, прогрессирование, прогноз, факторы.
________________________________________________
Key words: non-alcoholic fatty liver disease, fibrosis, progression, prognosis, factors.
Полный текст
Список литературы
1. EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. EASL-EASD-EASO. J Hepatol 2016; 64 (6): 1388–402.
2. Ивашкин В.Т. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31–41.
[Ivashkin V.T. et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2015; 6: 31–41 (in Russian).]
3. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. 2012. http://www.worldgastroenterology.org/ NAFLD-NASH.html.
4. Ивашкин В.Т. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей. Российское общество по изучению печени. М., 2015.
[Ivashkin V.T. Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors. Russian Society for the Study of the Liver. Moscow, 2015 (in Russian).]
5. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17 (11): 863–9.
6. Loomba R et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015; 149 (7): 1784–93.
7. Кононов А.В., Ливзан М.А. Медицина, основанная на доказательствах, в практике клинического патолога. Сибирский Консилиум. 2002; 2: 18–22.
[Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).]
8. Hossain N et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (11): 1224–29.
9. Bertot LC, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. J Mol Sci 2016; 17 (5): 774.
10. Chalasani N et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepato-logy 2012; 55 (6): 2005–23.
11. McPherson S et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (9): 1265–9.
12. Klair JS et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64 (1): 85–91.
13. Yang JD et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59 (4): 1406–14.
14. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215–24.
15. Mohanty SR et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50 (4): 797–804.
16. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35: 221–35.
17. Драпкина О.М., Попова И.В., Ивашкин В.Т. Влияние инсулинорезистентности на развитие неалкогольной жировой болезни печени и артериальной гипертензии у пациентов с ожирением. Врач. 2012; 8: 19–23.
[Drapkina O.M., Popova I.V., Ivashkin V.T. Vliianie insulinorezistentnosti na razvitie nealkogol'noi zhirovoi bolezni pecheni i arterial'noi gipertenzii u patsientov s ozhireniem. Vrach. 2012; 8: 19–23 (in Russian).]
18. Кособян Е.П., Смирнова О.М. Современные концепции патогенеза неалкогольной жировой болезни печени. Сахарный диабет. 2010; 1: 55–64.
[Kosobian E.P., Smirnova O.M. Sovremennye kontseptsii patogeneza nealkogol'noi zhirovoi bolezni pecheni. Sakharnyi diabet. 2010; 1: 55–64 (in Russian).]
19. Marchesini G et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
20. Bugianesi E et al. Insulin resistance in non- diabetic patients with non- alcoholic fatty liver disease: sites and mechanisms. Diabetogia 2005; 48 (4): 634–42.
21. Mazzotti A et al. Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. Dig Dis 2016; 34 (1): 3–10.
22. Zelber-Sagi S et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatology 2007; 47 (5): 711–7.
23. Assy N et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Canad J Gastroenterol 2008; 22 (10): 811–6.
24. Stanhope KL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119 (5): 1322–34.
25. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146 (3): 726–35.
26. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA). Mol Basis Dis 2015; 1852 (9): 1765–78.
27. Alferink LJ et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2019; 68 (6): 1088–98.
28. Chang Y et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419–25.
29. Hassan K et al. Non-alcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20 (34): 12082–101.
30. Ливзан М.А., Колбина М.В., Матошина И.В. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казан. мед. школы. 2014; 1 (4): 44–8.
[Livzan M.A., Kolbina M.V., Matoshina I.V. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazan. med. shkoly. 2014; 1 (4): 44–8 (in Russian).]
31. Stojsavljevic S et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (48): 18070–91.
32. Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab 2015; 26 (3): 153–61.
33. Haitao Pan, Jiao Guo, Zhengquan Su. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 157–69.
34. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Эксперимент. и клин. гастроэнтерология. 2014; 8 (108): 27–33.
[Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperiment. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).]
35. Joong-Won Park et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 5: 23.
36. Gastaldelli A, Kozakova M, Hojlund Gastaldelli K. Fatty Liver Is Associated with Insulin Resistance, Risk of Coronary Heart Disease, and Early Atherosclerosis in a Large European Population. Hepatology 2009; 49: 1537–44.
37. Raman M et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7): 868–75.
38. Gabele E et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011; 55 (6): 1391–9.
39. Miele L et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49 (6): 1877–87.
40. Ливзан М.А., Кролевец Т.С., Лаптева И.В., Черкащенко Н.А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014; 3 (4): 8–14.
[Livzan M.A., Krolevets T.S., Lapteva I.V., Cherkashchenko N.A. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).]
41. Кролевец Т.С., Ливзан М.А., Лаптева И.В., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Мед. совет. 2015; 13: 58–62.
[Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).]
42. Кролевец Т.С., Ливзан М.А., Лаптева И.В. Уровень матриксных металлопротеиназ и их тканевых ингибиторов как неинвазивный маркер функционального состояния печени при неалкогольной жировой болезни. Эксперимент. и клин. гастроэнтерология. 2016; 7 (131): 25–31.
[Krolevets T.S., Livzan M.A., Lapteva I.V. Uroven' matriksnykh metalloproteinaz i ikh tkanevykh ingibitorov kak neinvazivnyi marker funktsional'nogo sostoianiia pecheni pri nealkogol'noi zhirovoi bolezni. Eksperiment. i klin. gastroenterologiia. 2016; 7 (131): 25–31 (in Russian).]
43. Кролевец Т.С., Ливзан М.А., Чебаненко Е.В. и др. Прогностическая модель неинвазивной оценки формирования и прогрессирования фиброза печени у пациентов с неалкогольной жировой болезнью печени. Совр. проблемы науки и образования. 2018; 3. http: //www.science-education.ru/ru/article/view?id=27713
[Krolevets T.S., Livzan M.A., Chebanenko E.V. et al. Prognosticheskaia model' neinvazivnoi otsenki formirovaniia i progressirovaniia fibroza pecheni u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni. Sovr. problemy nauki i obrazovaniia. 2018; 3. http: //www.science-education.ru/ru/article/view?id=27713 (in Russian).]
44. Кролевец Т.С., Ливзан М.А., Николаев Н.А. и др. Свидетельство №2018616153 РФ. Автоматизированная система прогноза фиброза при неалкогольной жировой болезни печени; свидетельство о государственной регистрации программы для ЭВМ. Заявит. и правообл. ГОУ Омский мед. ун-т. №2018613113; заявл. 03.04.2018; зарегистрирован в реестре программ для ЭВМ 24.05.2018.
[T.S., Livzan M.A., Nikolaev N.A. et al. Svidetel'stvo №2018616153 RF. Avtomatizirovannaia sistema prognoza fibroza pri nealkogol'noi zhirovoi bolezni pecheni; svidetel'stvo o gosudarstvennoi registratsii programmy dlia EVM. Zaiavit. i pravoobl. GOU Omskii med. un-t. №2018613113; zaiavl. 03.04.2018; zaregistrirovan v reestre programm dlia EVM 24.05.2018 (in Russian).]
2. Ivashkin V.T. et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2015; 6: 31–41 (in Russian).
3. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. 2012. http://www.worldgastroenterology.org/ NAFLD-NASH.html.
4. Ivashkin V.T. Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors. Russian Society for the Study of the Liver. Moscow, 2015 (in Russian).
5. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17 (11): 863–9.
6. Loomba R et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015; 149 (7): 1784–93.
7. Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).
8. Hossain N et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (11): 1224–29.
9. Bertot LC, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. J Mol Sci 2016; 17 (5): 774.
10. Chalasani N et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepato-logy 2012; 55 (6): 2005–23.
11. McPherson S et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (9): 1265–9.
12. Klair JS et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64 (1): 85–91.
13. Yang JD et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59 (4): 1406–14.
14. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215–24.
15. Mohanty SR et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50 (4): 797–804.
16. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35: 221–35.
17. Drapkina O.M., Popova I.V., Ivashkin V.T. Vliianie insulinorezistentnosti na razvitie nealkogol'noi zhirovoi bolezni pecheni i arterial'noi gipertenzii u patsientov s ozhireniem. Vrach. 2012; 8: 19–23 (in Russian).
18. Kosobian E.P., Smirnova O.M. Sovremennye kontseptsii patogeneza nealkogol'noi zhirovoi bolezni pecheni. Sakharnyi diabet. 2010; 1: 55–64 (in Russian).
19. Marchesini G et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
20. Bugianesi E et al. Insulin resistance in non- diabetic patients with non- alcoholic fatty liver disease: sites and mechanisms. Diabetogia 2005; 48 (4): 634–42.
21. Mazzotti A et al. Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. Dig Dis 2016; 34 (1): 3–10.
22. Zelber-Sagi S et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatology 2007; 47 (5): 711–7.
23. Assy N et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Canad J Gastroenterol 2008; 22 (10): 811–6.
24. Stanhope KL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119 (5): 1322–34.
25. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146 (3): 726–35.
26. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA). Mol Basis Dis 2015; 1852 (9): 1765–78.
27. Alferink LJ et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2019; 68 (6): 1088–98.
28. Chang Y et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419–25.
29. Hassan K et al. Non-alcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20 (34): 12082–101.
30. Livzan M.A., Kolbina M.V., Matoshina I.V. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazan. med. shkoly. 2014; 1 (4): 44–8 (in Russian).
31. Stojsavljevic S et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (48): 18070–91.
32. Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab 2015; 26 (3): 153–61.
33. Haitao Pan, Jiao Guo, Zhengquan Su. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 157–69.
34. Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperiment. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).
35. Joong-Won Park et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 5: 23.
36. Gastaldelli A, Kozakova M, Hojlund Gastaldelli K. Fatty Liver Is Associated with Insulin Resistance, Risk of Coronary Heart Disease, and Early Atherosclerosis in a Large European Population. Hepatology 2009; 49: 1537–44.
37. Raman M et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7): 868–75.
38. Gabele E et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011; 55 (6): 1391–9.
39. Miele L et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49 (6): 1877–87.
40. Livzan M.A., Krolevets T.S., Lapteva I.V., Cherkashchenko N.A. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).
41. Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).
42. Krolevets T.S., Livzan M.A., Lapteva I.V. Uroven' matriksnykh metalloproteinaz i ikh tkanevykh ingibitorov kak neinvazivnyi marker funktsional'nogo sostoianiia pecheni pri nealkogol'noi zhirovoi bolezni. Eksperiment. i klin. gastroenterologiia. 2016; 7 (131): 25–31 (in Russian).
43. Krolevets T.S., Livzan M.A., Chebanenko E.V. et al. Prognosticheskaia model' neinvazivnoi otsenki formirovaniia i progressirovaniia fibroza pecheni u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni. Sovr. problemy nauki i obrazovaniia. 2018; 3. http: //www.science-education.ru/ru/article/view?id=27713 (in Russian).
44. T.S., Livzan M.A., Nikolaev N.A. et al. Svidetel'stvo №2018616153 RF. Avtomatizirovannaia sistema prognoza fibroza pri nealkogol'noi zhirovoi bolezni pecheni; svidetel'stvo o gosudarstvennoi registratsii programmy dlia EVM. Zaiavit. i pravoobl. GOU Omskii med. un-t. №2018613113; zaiavl. 03.04.2018; zaregistrirovan v reestre programm dlia EVM 24.05.2018 (in Russian).
2. Ивашкин В.Т. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31–41.
[Ivashkin V.T. et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2015; 6: 31–41 (in Russian).]
3. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. 2012. http://www.worldgastroenterology.org/ NAFLD-NASH.html.
4. Ивашкин В.Т. Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей. Российское общество по изучению печени. М., 2015.
[Ivashkin V.T. Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors. Russian Society for the Study of the Liver. Moscow, 2015 (in Russian).]
5. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17 (11): 863–9.
6. Loomba R et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015; 149 (7): 1784–93.
7. Кононов А.В., Ливзан М.А. Медицина, основанная на доказательствах, в практике клинического патолога. Сибирский Консилиум. 2002; 2: 18–22.
[Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).]
8. Hossain N et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (11): 1224–29.
9. Bertot LC, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. J Mol Sci 2016; 17 (5): 774.
10. Chalasani N et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepato-logy 2012; 55 (6): 2005–23.
11. McPherson S et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (9): 1265–9.
12. Klair JS et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64 (1): 85–91.
13. Yang JD et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59 (4): 1406–14.
14. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215–24.
15. Mohanty SR et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50 (4): 797–804.
16. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35: 221–35.
17. Драпкина О.М., Попова И.В., Ивашкин В.Т. Влияние инсулинорезистентности на развитие неалкогольной жировой болезни печени и артериальной гипертензии у пациентов с ожирением. Врач. 2012; 8: 19–23.
[Drapkina O.M., Popova I.V., Ivashkin V.T. Vliianie insulinorezistentnosti na razvitie nealkogol'noi zhirovoi bolezni pecheni i arterial'noi gipertenzii u patsientov s ozhireniem. Vrach. 2012; 8: 19–23 (in Russian).]
18. Кособян Е.П., Смирнова О.М. Современные концепции патогенеза неалкогольной жировой болезни печени. Сахарный диабет. 2010; 1: 55–64.
[Kosobian E.P., Smirnova O.M. Sovremennye kontseptsii patogeneza nealkogol'noi zhirovoi bolezni pecheni. Sakharnyi diabet. 2010; 1: 55–64 (in Russian).]
19. Marchesini G et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
20. Bugianesi E et al. Insulin resistance in non- diabetic patients with non- alcoholic fatty liver disease: sites and mechanisms. Diabetogia 2005; 48 (4): 634–42.
21. Mazzotti A et al. Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. Dig Dis 2016; 34 (1): 3–10.
22. Zelber-Sagi S et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatology 2007; 47 (5): 711–7.
23. Assy N et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Canad J Gastroenterol 2008; 22 (10): 811–6.
24. Stanhope KL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119 (5): 1322–34.
25. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146 (3): 726–35.
26. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA). Mol Basis Dis 2015; 1852 (9): 1765–78.
27. Alferink LJ et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2019; 68 (6): 1088–98.
28. Chang Y et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419–25.
29. Hassan K et al. Non-alcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20 (34): 12082–101.
30. Ливзан М.А., Колбина М.В., Матошина И.В. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник казан. мед. школы. 2014; 1 (4): 44–8.
[Livzan M.A., Kolbina M.V., Matoshina I.V. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazan. med. shkoly. 2014; 1 (4): 44–8 (in Russian).]
31. Stojsavljevic S et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (48): 18070–91.
32. Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab 2015; 26 (3): 153–61.
33. Haitao Pan, Jiao Guo, Zhengquan Su. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 157–69.
34. Ливзан М.А., Лаптева И.В., Миллер Т.С. Роль лептина и лептинорезистентности в формировании неалкогольной жировой болезни печени у лиц с ожирением и избыточной массой тела. Эксперимент. и клин. гастроэнтерология. 2014; 8 (108): 27–33.
[Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperiment. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).]
35. Joong-Won Park et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 5: 23.
36. Gastaldelli A, Kozakova M, Hojlund Gastaldelli K. Fatty Liver Is Associated with Insulin Resistance, Risk of Coronary Heart Disease, and Early Atherosclerosis in a Large European Population. Hepatology 2009; 49: 1537–44.
37. Raman M et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7): 868–75.
38. Gabele E et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011; 55 (6): 1391–9.
39. Miele L et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49 (6): 1877–87.
40. Ливзан М.А., Кролевец Т.С., Лаптева И.В., Черкащенко Н.А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014; 3 (4): 8–14.
[Livzan M.A., Krolevets T.S., Lapteva I.V., Cherkashchenko N.A. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).]
41. Кролевец Т.С., Ливзан М.А., Лаптева И.В., Черкащенко Н.А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Мед. совет. 2015; 13: 58–62.
[Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).]
42. Кролевец Т.С., Ливзан М.А., Лаптева И.В. Уровень матриксных металлопротеиназ и их тканевых ингибиторов как неинвазивный маркер функционального состояния печени при неалкогольной жировой болезни. Эксперимент. и клин. гастроэнтерология. 2016; 7 (131): 25–31.
[Krolevets T.S., Livzan M.A., Lapteva I.V. Uroven' matriksnykh metalloproteinaz i ikh tkanevykh ingibitorov kak neinvazivnyi marker funktsional'nogo sostoianiia pecheni pri nealkogol'noi zhirovoi bolezni. Eksperiment. i klin. gastroenterologiia. 2016; 7 (131): 25–31 (in Russian).]
43. Кролевец Т.С., Ливзан М.А., Чебаненко Е.В. и др. Прогностическая модель неинвазивной оценки формирования и прогрессирования фиброза печени у пациентов с неалкогольной жировой болезнью печени. Совр. проблемы науки и образования. 2018; 3. http: //www.science-education.ru/ru/article/view?id=27713
[Krolevets T.S., Livzan M.A., Chebanenko E.V. et al. Prognosticheskaia model' neinvazivnoi otsenki formirovaniia i progressirovaniia fibroza pecheni u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni. Sovr. problemy nauki i obrazovaniia. 2018; 3. http: //www.science-education.ru/ru/article/view?id=27713 (in Russian).]
44. Кролевец Т.С., Ливзан М.А., Николаев Н.А. и др. Свидетельство №2018616153 РФ. Автоматизированная система прогноза фиброза при неалкогольной жировой болезни печени; свидетельство о государственной регистрации программы для ЭВМ. Заявит. и правообл. ГОУ Омский мед. ун-т. №2018613113; заявл. 03.04.2018; зарегистрирован в реестре программ для ЭВМ 24.05.2018.
[T.S., Livzan M.A., Nikolaev N.A. et al. Svidetel'stvo №2018616153 RF. Avtomatizirovannaia sistema prognoza fibroza pri nealkogol'noi zhirovoi bolezni pecheni; svidetel'stvo o gosudarstvennoi registratsii programmy dlia EVM. Zaiavit. i pravoobl. GOU Omskii med. un-t. №2018613113; zaiavl. 03.04.2018; zaregistrirovan v reestre programm dlia EVM 24.05.2018 (in Russian).]
________________________________________________
2. Ivashkin V.T. et al. Rasprostranennost' nealkogol'noi zhirovoi bolezni pecheni u patsientov ambulatorno-poliklinicheskoi praktiki v Rossiiskoi Federatsii: rezul'taty issledovaniia DIREG 2. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2015; 6: 31–41 (in Russian).
3. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. 2012. http://www.worldgastroenterology.org/ NAFLD-NASH.html.
4. Ivashkin V.T. Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors. Russian Society for the Study of the Liver. Moscow, 2015 (in Russian).
5. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17 (11): 863–9.
6. Loomba R et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology. 2015; 149 (7): 1784–93.
7. Kononov A.V., Livzan M.A. Meditsina, osnovannaia na dokazatel'stvakh, v praktike klinicheskogo patologa. Sibirskii Konsilium. 2002; 2: 18–22 (in Russian).
8. Hossain N et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (11): 1224–29.
9. Bertot LC, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. J Mol Sci 2016; 17 (5): 774.
10. Chalasani N et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepato-logy 2012; 55 (6): 2005–23.
11. McPherson S et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (9): 1265–9.
12. Klair JS et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64 (1): 85–91.
13. Yang JD et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59 (4): 1406–14.
14. Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis 2016; 20: 215–24.
15. Mohanty SR et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50 (4): 797–804.
16. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35: 221–35.
17. Drapkina O.M., Popova I.V., Ivashkin V.T. Vliianie insulinorezistentnosti na razvitie nealkogol'noi zhirovoi bolezni pecheni i arterial'noi gipertenzii u patsientov s ozhireniem. Vrach. 2012; 8: 19–23 (in Russian).
18. Kosobian E.P., Smirnova O.M. Sovremennye kontseptsii patogeneza nealkogol'noi zhirovoi bolezni pecheni. Sakharnyi diabet. 2010; 1: 55–64 (in Russian).
19. Marchesini G et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
20. Bugianesi E et al. Insulin resistance in non- diabetic patients with non- alcoholic fatty liver disease: sites and mechanisms. Diabetogia 2005; 48 (4): 634–42.
21. Mazzotti A et al. Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. Dig Dis 2016; 34 (1): 3–10.
22. Zelber-Sagi S et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatology 2007; 47 (5): 711–7.
23. Assy N et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Canad J Gastroenterol 2008; 22 (10): 811–6.
24. Stanhope KL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119 (5): 1322–34.
25. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146 (3): 726–35.
26. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA). Mol Basis Dis 2015; 1852 (9): 1765–78.
27. Alferink LJ et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut 2019; 68 (6): 1088–98.
28. Chang Y et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009; 58: 1419–25.
29. Hassan K et al. Non-alcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20 (34): 12082–101.
30. Livzan M.A., Kolbina M.V., Matoshina I.V. et al. Gormony zhirovoi tkani i nealkogol'naia zhirovaia bolezn' pecheni pri metabolicheskom sindrome. Dnevnik kazan. med. shkoly. 2014; 1 (4): 44–8 (in Russian).
31. Stojsavljevic S et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20 (48): 18070–91.
32. Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab 2015; 26 (3): 153–61.
33. Haitao Pan, Jiao Guo, Zhengquan Su. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 157–69.
34. Livzan M.A., Lapteva I.V., Miller T.S. Rol' leptina i leptinorezistentnosti v formirovanii nealkogol'noi zhirovoi bolezni pecheni u lits s ozhireniem i izbytochnoi massoi tela. Eksperiment. i klin. gastroenterologiia. 2014; 8 (108): 27–33 (in Russian).
35. Joong-Won Park et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 5: 23.
36. Gastaldelli A, Kozakova M, Hojlund Gastaldelli K. Fatty Liver Is Associated with Insulin Resistance, Risk of Coronary Heart Disease, and Early Atherosclerosis in a Large European Population. Hepatology 2009; 49: 1537–44.
37. Raman M et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11 (7): 868–75.
38. Gabele E et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011; 55 (6): 1391–9.
39. Miele L et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49 (6): 1877–87.
40. Livzan M.A., Krolevets T.S., Lapteva I.V., Cherkashchenko N.A. Nealkogol'naia zhirovaia bolezn' pecheni u lits s abdominal'nym tipom ozhireniia. Dokazatel'naia gastroenterologiia. 2014; 3 (4): 8–14 (in Russian).
41. Krolevets T.S., Livzan M.A., Lapteva I.V., Cherkashchenko N.A. Leptinorezistentnost' u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni, assotsiirovannoi s ozhireniem i izbytochnoi massoi tela. Med. sovet. 2015; 13: 58–62 (in Russian).
42. Krolevets T.S., Livzan M.A., Lapteva I.V. Uroven' matriksnykh metalloproteinaz i ikh tkanevykh ingibitorov kak neinvazivnyi marker funktsional'nogo sostoianiia pecheni pri nealkogol'noi zhirovoi bolezni. Eksperiment. i klin. gastroenterologiia. 2016; 7 (131): 25–31 (in Russian).
43. Krolevets T.S., Livzan M.A., Chebanenko E.V. et al. Prognosticheskaia model' neinvazivnoi otsenki formirovaniia i progressirovaniia fibroza pecheni u patsientov s nealkogol'noi zhirovoi bolezn'iu pecheni. Sovr. problemy nauki i obrazovaniia. 2018; 3. http: //www.science-education.ru/ru/article/view?id=27713 (in Russian).
44. T.S., Livzan M.A., Nikolaev N.A. et al. Svidetel'stvo №2018616153 RF. Avtomatizirovannaia sistema prognoza fibroza pri nealkogol'noi zhirovoi bolezni pecheni; svidetel'stvo o gosudarstvennoi registratsii programmy dlia EVM. Zaiavit. i pravoobl. GOU Omskii med. un-t. №2018613113; zaiavl. 03.04.2018; zaregistrirovan v reestre programm dlia EVM 24.05.2018 (in Russian).
Авторы
Т.С. Кролевец*, М.А. Ливзан
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*mts-8-90@mail.ru
Omsk State Medical University, Omsk, Russia
*mts-8-90@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*mts-8-90@mail.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*mts-8-90@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.